We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Global Point-of-Care Coagulation Testing Market to Be Driven by Growing Geriatric Population

By LabMedica International staff writers
Posted on 08 Dec 2021
Print article
Illustration
Illustration

The global point-of-care (POC) coagulation testing market is set to achieve significant growth on the back of the growing geriatric population and increasing technological innovations in POC testing, although the lack of trained professionals will hamper market growth.

These are the latest findings of Technavio (New York, NY, USA), a global technology research and advisory company.

The growing geriatric population is expected to fuel the growth of the POC coagulation testing market. Aging increases the susceptibility to infections as the immune system deteriorates with age. Older adults require diagnostic testing on a regular basis due to their low immunity and slow metabolism. These factors have increased the demand for POC blood coagulation analyzers as coagulation measurements can assist in diagnosing diseases. Physicians use the results of these blood tests to choose the most suitable line of treatment. Hence, an increasing older adult population indicates a growing demand for POC coagulation testing, thus contributing to the market growth.

However, the inability to hire trained professionals will limit the use of POC coagulation analyzers, which could hinder market growth. There is a shortage of these specialists in diagnostic centers and hospitals globally. Generally, most rural hospitals face issues such as the lack of patient volume required to justify having specialists. Most times, appointing in-house specialists is cost-prohibitive, especially for small medical facilities. Therefore, end-users such as hospitals and diagnostic centers will need to invest significantly in providing training to their employees for laboratory testing and maintaining POC coagulation analyzers.

The hospitals and clinics segment hold the largest share of the global POC coagulation testing market and will be the key driver of the market growth, owing to the significant use of POC coagulation testing analyzers during perioperative procedures for the timely determination of coagulopathies (bleeding disorders) and hemostatic functions in patients. This helps in preventing unanticipated bleeding and perioperative mortality. Hospitals and clinics use globally accepted POC coagulation testing procedures such as aPTT and INR, which significantly reduce the turnaround time and allow medical practitioners to make fast decisions during critical situations.

Geographically, a majority of the growth of the global POC coagulation testing market will originate from North America due to an increase in laboratory automation, a shift toward rapid diagnostic tests, and increased number of Food & Drug Administration (FDA) approvals for new diagnostic procedures such as liquid biopsy and microbial tests. The US is a key market for POC coagulation testing in North America. However, the North American market for POC coagulation testing is expected to grow at a slower pace than the market in Asia and Europe.

Related Links:
Technavio 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more